Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques

Graphical abstract

Highlights
- HIV-Env SOSIP trimers induce neutralizing antibodies in cynomolgus macaques
- Vaccine-induced innate cells changes are characterized using mass cytometry
- Adjuvant and route of immunization influence early innate signatures in vaccinated NHP
- Early innate cell signatures predict neutralizing antibody levels

Authors
Matthieu Van Tilbeurgh, Pauline Maisonnasse, Jean-Louis Palgen, ..., Gabriella Scarlatti, Rogier W. Sanders, Roger Le Grand

Correspondence
roger.le-grand@cea.fr

In brief
Van Tilbeurgh et al. use mass cytometry to identify innate cell signature predictive of neutralizing antibody response in a non-human primate model. They highlight that better understanding early immune mechanisms may be of great help to design new vaccine candidates.
Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques

Matthieu Van Tilbeurgh,1 Pauline Maisonnasse,1 Jean-Louis Palgen,1 Monica Tolazzi,2 Yoann Aldon,3 Nathalie Dereudre-Bosquet,1 Mariangela Cavarelli,1 Anne-Sophie Beignon,1 Ernesto Marcos-Lopez,1 Anne-Sophie Gallouet,1 Emmanuel Gilson,4 Gabriel Ozorowski,5 Andrew B. Ward,5 Ilja Bontjer,6 Paul F. McKay,3 Robin J. Shattock,3 Gabriella Scarlatti,2 Rogier W. Sanders,6,7 and Roger Le Grand1,8,*

1Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
2Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
3Imperial College London, Faculty of Medicine, Department of Infectious Disease, London, UK
4Life & Soft, 28 rue de la Redoute, 92260 Fontenay-aux-Roses, France
5Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
6Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
7Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
8Lead contact
*Correspondence: roger.le-grand@cea.fr
https://doi.org/10.1016/j.xcrm.2022.100751

SUMMARY

Given the time and resources invested in clinical trials, innovative prediction methods are needed to decrease late-stage failure in vaccine development. We identify combinations of early innate responses that predict neutralizing antibody (nAb) responses induced in HIV-Env SOSIP immunized cynomolgus macaques using various routes of vaccine injection and adjuvants. We analyze blood myeloid cells before and 24 h after each immunization by mass cytometry using a three-step clustering, and we discriminate unique vaccine signatures based on HLA-DR, CD39, CD86, CD11b, CD45, CD64, CD14, CD32, CD11c, CD123, CD4, CD16, and CADM1 surface expression. Various combinations of these markers characterize cell families positively associated with nAb production, whereas CADM1-expressing cells are negatively associated (p < 0.05). Our results demonstrate that monitoring immune signatures during early vaccine development could assist in identifying biomarkers that predict vaccine immunogenicity.

INTRODUCTION

HIV-1 is responsible for a pandemic of more than 37 million people and continues to spread at a rate of >1.7 million new infections every year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic. Despite decades of research, we do not yet have a vaccine capable of protecting people from HIV-1 infection or halting disease progression. Developing new strategies for HIV vaccines requires a long-term effort challenging the investment in the designing of immunogens and immunization modalities while reducing the risk of failure in the late stages of development.

Vaccine development failure may result from our poor understanding of immune mechanisms of protection following immunization as only a few immune parameters are assessed during efficacy trials. Seeding studies from R.P. Sekal and B. Pulendran have revealed system biology as a promising and powerful exploration tool, taking advantage of wide multiplexed data, allowing a deep understanding of cellular and molecular partners implicated in immune responses. Systems vaccinology has been applied to multiple vaccine approaches, including yellow fever, HIV, influenza and recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) vaccines, and to identify adjuvant immune signature. Tsang et al. even described host blood parameters, predicting before immunization the capacity to respond to influenza vaccine. Thus, systems vaccinology may contribute to reduce vaccine development failure by identifying markers that predict protective immunity at the early stages of preclinical animal model studies and clinical trials.

Studies in animal models are critical in vaccine development. Non-human primates (NHPs) are particularly relevant because of the close phylogenetic relationship with humans, resulting in a very similar organization of the respective immune systems, allowing testing immunogenicity without requiring
adaptation of the candidate vaccine to the species. Cynomolgus and rhesus macaques are widely used in the development of an HIV vaccine, because simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) challenge models also recapitulate most of the features of HIV infection and acquired immunodeficiency syndrome (AIDS) in humans.11,12

Innate immunity is one of the first players in shaping the vaccine-induced immune responses, and molecular and cellular changes immediately following vaccine injection may help to identify markers predicting the orientation, durability, and efficacy of the adaptive response. Such predictive signals would be particularly useful to accelerate the selection of the most promising vaccine candidates at early developmental stages.

Here, we demonstrate in cynomolgus macaques that subsets of myeloid cells, characterized by mass cytometry and appearing in blood very early following the injection of native-like trimeric HIV-1 envelope SOSIP (Env) immunogens,13,14 differ depending on the given adjuvant and immunization route. Moreover, we identified a set of cell markers that correlates with vaccine-induced neutralizing antibody (nAb) activity that could be used to develop models that predict the quality of the vaccine response.

**RESULTS**

**The humoral response to an HIV SOSIP Env vaccine is influenced by both the injection route and the adjuvant**

We characterized the vaccine-induced response in three groups of six cynomolgus macaques to a stabilized Env derived from a consensus sequence of HIV-1 group M (ConM SOSIP.v7) that we previously reported to induce strong nAb responses in rabbits,15,16 which is being evaluated in phase 1 trials in humans (NCT03816137, NCT03961438, NCT04046978). We assessed the impact of subcutaneous (SC) or intramuscular (IM) immunization in combination with squalene emulsion (SQ) or monophosphoryl-lipid A liposome (MPLA) adjuvants (Figure 1). The adjuvants were shown not to compromise the conformational integrity of the ConM SOSIP.v7 trimers (Figure S1).

Animals immunized IM with MPLA (Group 1) or SQ (Group 3) showed similar levels of ConM-specific IgG (838,307.004 ± 2.163 and 1,622,973.717 ± 1.737 area under the curve [AUC], respectively [geometric mean ± geometric SD]) and nAb titers (22,610.1922 ± 2.642 and 18,488.409 ± 2.268 AUC, respectively), with peaks at 2 weeks after the first and second boost (week (W) 10 and 26, respectively), suggesting that both adjuvants are as effective by the IM route (Figures 2A–2D and S2). In both groups, ConM-specific IgG levels remained high after
reaching a peak 2 weeks after each boost, while nAb titers dropped after the first (16.288 ± 1.716 and 20.246 ± 2.461 ng/mL, respectively) and to a lesser extent after the second boost (41.296 ± 2.906 and 202.250 ± 2.945 ng/mL, respectively). In contrast, MPLA-SC immunization (Group 2) induced significantly lower ConM-specific IgG levels (1421.370 ± 7.028 AUC) compared with MPLA-IM and SQ-IM immunizations (p = 0.041 and p = 0.015, respectively, Figure 2C), especially at W10 (Figure 2E).

Neutralization to conM was observed in the MPLA-SC group only after the third immunization with heterogeneous nAb titers. Notwithstanding, neutralizing titers tended to be lower in the MPLA-SC group despite two animals displaying equivalent titers to the lowest and highest of the IM groups (Figure 2F). Heterologous neutralization against the highly neutralization-sensitive 93MW965.26 (MW965) pseudotyped virus (PSV) at W28 was also assessed. Neutralization of MW965 was 10- to 100-fold lower than that of ConM, but similar trends were observed between groups (Figure S3).

We then compared Fcγ-receptor IIIa (FcγRIIIa) binding characteristics of ConM SOSIP.v7-induced serum Ab between the three groups. This has been shown to provide an indirect read-out for Ag-specific antibody-dependent cellular cytotoxicity.
(ADCC). Similarly to nAb titers, a sharp increase of recombinant soluble (rs) FcγRIIa binding activity was observed in both IM groups after each boost followed by a decrease. We observed that the SQ formulation generated higher rsFcγRIIa binding levels than MPLA by the IM route with both groups inducing significantly higher rsFcγRIIa binding activity than the MPLA-SC induced (Figure 2G). Although the SQ-IM group displayed a more homogeneous response, levels of binding became significantly higher than the MPLA-IM group after the third injection (W26, p = 0.0411; W28, p = 0.026) (Figure 2H). These results highlight that not only the route but also the adjuvant impact rsFcR binding activity. Overall, we demonstrated that ConM SOSIP.v7-specific humoral responses were more efficiently induced by the IM than the SC route.

Both the adjuvant and route of immunization affect myeloid cell dynamics

The route- and adjuvant-dependent differences we observed in the anti-Env antibody response argue for a role of early innate immunity in shaping the nAb response. Here, we focused on the myeloid cell compartment because of its role in capturing and presenting vaccine antigens to B and T lymphocytes, in addition to its contribution to inflammation. Mass cytometry was used to extensively characterize the differentiation and functional markers in the heterogeneous blood cell population. Importantly, many of the cell markers we studied in cynomolgus macaques have human counterparts, emphasizing the relevance of this species as a model for evaluating human candidate vaccines. In addition, the antibody panel used in our study consisted of anti-human antibodies cross-reacting with macaque cell markers, thus facilitating the translatability of preclinical study protocols to human clinical trials samples.

A spanning-tree progression analysis of density-normalized events (SPADE) was performed on mass cytometry-generated data to identify leukocyte clusters displaying similar phenotypes (Figure S4A). Major cell populations were defined based on CD3, CD4, CD8, CD20, and HLA-DR expression, which allowed for the identification of 225 myeloid cell clusters (Lin−/CD14−/CD11c−). Based on cell population dynamics following vaccine injection, MPLA-IM induced stronger mobilization of total myeloid cells than the other adjuvants and routes within the first 24 h (Figures S4B–S4D). Granulocytes were not evaluated in this study due to the technical limitation of using frozen and thawed whole blood samples. To better visualize the cluster phenotypes, we then performed hierarchical clustering based on their relative marker levels (Figure 3). Clusters displaying similar phenotypes were gathered into 28 phenotypic families (PFs), described in Table 1. The cluster dendrogram divides the PFs into three superfamilies: (1) HLA-DR+/CD14+/CD11b+, which we identified as monocytes, (2) HLA-DRmid/CD14−/CD11c−, which we identified as a subset of dendritic cells (DCs), and (3) HLA-DRlo/CD14+/CD11c−/CD16−, which we identified as another subset of DCs. We determined the impact of ConM SOSIP.v7 immunization on these populations by investigating the differences in cell abundance at different time points after vaccination (Figure 4A and S5 and Table S1). The MPLA-IM group showed significant changes in the myeloid compartment with the frequency of nine PFs significantly increased as early as 24 h following the first injection. In both MPLA-SC and SQ-IM groups, non-classical monocytes (PF19, p = 0.03), intermediate monocytes (PF22, p = 0.03), and moDCs (PF2, PF15, PF25, p = 0.03). These last PFs displayed the most significant changes through time for all vaccines, especially for MPLA-IM (Figure 4B). The first injection only induced an increase in the frequency of cDC1-like cells (PF28, p = 0.03), CDC1-like cells (PF28, PF26, and PF16, p = 0.03), and HLA-DR−/CD11c−/CD16− DCs (PF14, p = 0.03). The first boost injection only mobilized monocyte populations (PF10, PF15, PF2, and PF25, p = 0.03). Finally, the second boost mobilized a much wider range of myeloid cells. In addition to the monocyte families, there was an increase in the frequency of cells with a macrophage phenotype (PF27, p = 0.03), cDC1-like cells (PF28, PF26, and PF16, p = 0.03), and HLA-DR−/CD11c−/CD16− DCs (PF17, PF4, PF5, PF14, PF6, and PF7, p = 0.03). Overall, the use of MPLA by the IM route appeared to mainly recruit and elicit monocyte/macrophage populations, with an important extension to DC populations after the third vaccine injection, compared with previous time points, indicating that there are host changes over time that affect the quality of the innate response.

The MPLA-SC group mostly displayed changes within the monocyte compartment. MoDCs (PF2, PF15, and PF25, p = 0.03) were the only subsets significantly induced 24 h after the first injection, along with a cDC2 subpopulation (PF24, p = 0.03). Similar to MPLA-IM, the second immunization mobilized classical monocytes (PF10, p = 0.03) and moDCs (PF2, PF15, and PF25, p = 0.03) as well as intermediate monocytes. Finally, seven PFs showed significant changes after the last immunization, with increasing frequencies of monocyte populations (PF2, PF15, PF22, PF25, p = 0.03), as well as cDC2 (PF24, p = 0.03) and HLA-DR−/CD11c−/CD16− DCs (PF4, p = 0.03). Conversely, the PF23 pDC subset showed a significant decrease relative to the baseline level. Thus, SC injection of MPLA shows similar monocyte mobilization as MPLA-IM but of lower amplitude. We found no significant amplification of DCs in the MPLA-SC group, highlighting the influence of the administration route on the quality of the innate response, despite the use of the same adjuvant.

Few significant differences were observed for this group when compared with the SQ-IM group. Most changes after the first injection occurred within the monocyte compartment (PF1, PF2, PF3, and PF19) except for the PF11 HLA-DRmid−/CD14−/CD11c− DC subpopulation. The frequency of classical PF1 and PF3 monocytes, non-classical PF19 monocytes, and PF11 cDC1 decreased after ConM SØSIP.v7 injection, whereas that of PF2 moDCs showed a marked increase relative to baseline levels. The second injection only mobilized PF2 moDCs, and we observed a loss of PF11 cDC1 and PF16/PF17 HLA-DRmid−/CD11c−/CD16− DCs. Finally, similar to groups 1 and 2, the final injection induced strong mobilization of PF2, PF15, and PF25 moDCs.

Vaccine-induced blood cell signatures

We identified vaccine signatures by performing linear discriminant analysis (LDA) (Figures 5A and 5B). We grouped PFs sharing close profiles of changes over time into eight kinetic families.
Figure 3. Phenotypic diversity of the blood myeloid cell compartment

The heatmap shows the hierarchical clustering and gathering of all myeloid cell SPADE clusters. Marker expression is shown in columns and cell clusters in rows. Twenty-eight phenotypic families were defined by proximity in the cluster dendrogram and manually annotated. The marker dendrogram represents markers with similar expression patterns. Markers used by SPADE unsupervised analysis for the clustering are written in bold.
| Kinetic families | Phenotypic families | Pop. characteristics | Subsets characteristics | Cell population | References |
|-----------------|--------------------|---------------------|------------------------|-----------------|------------|
| KF-I            | HLA-DR<sup>+</sup>, CD64<sup>hi</sup>, CD86<sup>hi</sup>, CD11b<sup>hi</sup> | 1                   | CD14<sup>lo</sup>, CD32<sup>mid</sup> | classical monocytes | Nakaya et al. 7; Tsang et al. 6; Trautmann and Sekaly 9; Mooney et al. 10; Reimann et al. 11; Estes et al. 12; Sanders and Moore 13; De Taeye et al. 14; Slipean et al. 15; Brouwer et al. 16 |
|                 |                    | 3                   | CD14<sup>lo</sup>, CD32<sup>+</sup> |                |            |
|                 |                    | 10                  | CD14<sup>lo</sup>, CD32<sup>hi</sup> |                |            |
|                 |                    | 15                  | CD14<sup>+</sup>, CD1c<sup>lo</sup> | MoDC           |            |
|                 |                    | 25                  | CD14<sup>+</sup>, CD1c<sup>hi</sup> |                |            |
|                 |                    | 19                  | CD14<sup>lo</sup>, CD16<sup>+</sup>, CD11c<sup>+</sup> | non-classical monocytes |            |
|                 |                    | 22                  | CD14<sup>+</sup>, CD16<sup>+</sup>, CD11c<sup>+</sup> | intermediate monocytes |            |
| KF-II           | HLA-DR<sup>+</sup>, CD32<sup>hi</sup>, CD64<sup>hi</sup>, CD86<sup>hi</sup>, CD11b<sup>hi</sup> | 2                   | CD14<sup>+</sup>, CD1c<sup>lo</sup> | MoDC | Reimann et al. 11; Zhang et al. 16 |
| HLA-DR<sup>+</sup> |                    | 20                  | FcεR1<sup>hi</sup>, CD32<sup>hi</sup>, CD86<sup>hi</sup>, CD4<sup>lo</sup> | putative cDC2 | Reimann et al. 11; De Taeye et al. 14; Wines et al. 17; Calabro et al. 19 |
|                 |                    | 9                   | CD1c<sup>+</sup>, FcεR1<sup>hi</sup>, CD32<sup>hi</sup>, CD86<sup>hi</sup>, CD4<sup>lo</sup> | cDC2 | |
|                 |                    | 24                  |                               |                |            |
| KF-III          | HLA-DR<sup>+</sup>, CD11c<sup>+</sup>, CD16<sup>+</sup>, CD32<sup>+</sup> | 28                  | CADM1<sup>+</sup> | cDC1 like DC | De Taeye et al. 14; Wines et al. 17 |
| HLA-DR<sup>+</sup> |                    | 4                   | /                      | DC | / |
|                 |                    | 5                   | /                      | DC | / |
|                 |                    | 6                   | /                      | DC | / |
|                 |                    | 7                   | /                      | DC | / |
|                 |                    | 14                  | /                      | DC | / |
| KF-IV           | HLA-DR<sup>+</sup>, CD32<sup>hi</sup>, CD64<sup>hi</sup>, CD86<sup>hi</sup>, CD11b<sup>hi</sup> | 8                   | CD14<sup>lo</sup> | classical monocytes | Nakaya et al. 7; Tsang et al. 6; Trautmann and Sekaly 9; Mooney et al. 10; Reimann et al. 11; Estes et al. 12; Sanders and Moore 13; De Taeye et al. 14; Slipean et al. 15; Brouwer et al. 16 |
| HLA-DR<sup>+</sup> |                    | 17                  | /                      | DC | / |
|                 |                    | 11                  | CADM1<sup>+</sup>, CD1c<sup>-</sup>, CD172a<sup>lo</sup>, CD16<sup>lo</sup> | cDC1 | De Taeye et al. 14; Wines et al. 17 |

(Continued on next page)
Table 1. Continued

| Kinetic families | Population characteristics | Phenotypic families | Subsets characteristics | Cell population* | References |
|-----------------|---------------------------|---------------------|-------------------------|-------------------|------------|
| KF-VI           | HLA-DR<sup>lo</sup>, CD123<sup>+</sup> | 21                  | CD1c<sup>+</sup>, FceRI<sup>hi</sup>, CD86<sup>mid</sup> CD123<sup>+</sup>, CD4<sup>+</sup> | immature cDC2    | Pauthner et al. 20 |
|                 |                           |                     |                         |                   |            |
| KF-VII          | HLA-DR<sup>lo</sup>, CD14<sup>+</sup>, CD11b<sup>+</sup>, CD64<sup>+</sup>, CD11c<sup>-</sup>, CD16<sup>-</sup> | 13                  | CCR5<sup>+</sup>, CXCR4<sup>+</sup>, CD62L<sup>-</sup> | pDC/blood DC precursor | Reimann et al. 11; Estes et al. 12; Wines et al. 17; Pauthner et al. 20; Calabro et al. 16; O’Hagan et al. 21; Rosenbaum et al. 22; Anderson et al. 23; Sanders et al. 24 |
|                 |                           |                     |                         |                   |            |
| KF-VIII         | HLA-DR<sup>lo</sup>, CD11c<sup>hi</sup>, CD16<sup>hi</sup> | 16                  | CADM1<sup>+</sup> | cDC1 like DC    | De Taeye et al. 14; Wines et al. 17 |
|                 |                           |                     |                         |                   |            |

The phenotypic composition of each kinetic family is detailed. The main phenotypic characteristics used to identify cell populations according to the expression profile shown in the heatmap (Figure 3) are indicated. *Proposal of cell annotation. Absence of data were indicated with /.
(KFs, Table 1), taking into account the correlation between variations in abundance among PFs (Figures S6 and S7 and Table S2). LDA differentiated the vaccine regimens for every time point (Figure 5A). Then, a second LDA was performed to identify KF associated to the vaccine regimens (Figure 5B). In this model, KF-III (CD11c−CD16+ DCs) was associated with MPLA-IM. Similarly, KF-VIII was associated with MPLA-SC, composed of two PFs (16 and 26) belonging to CD11c−CD16+ cell signature (Figure 5D), allowing to discriminate between vaccine regimens on the basis of high CADM1 expression.

Interestingly, three KFs for MPLA-IM (KF-II, III, and VII) and four for SQ-IM (KF-III, V, VII, and VIII) significantly correlated with nAb production (p < 0.05). KF-II, characterized by high expression of moDCs (PF2) and cDC2 (PF9, 20, 21, and 24) from KF-II but also immature cDC2 from KF-V and pDCs from KF-VI. Additionally, the LDA score of KF-I monocytes (PF1, 3, 10, 15, 19, 22, and 25), KF-VII (PF13 and 27), and KF-IV (PF8 and 17) did discriminate SQ-IM from MPLA vaccines but could not be associated either with MPLA-IM or MPLA-SC, suggesting an MPLA adjuvant signature for those KFs.

Next, we identified the main phenotypic differences between cell populations using the Kolmogorov-Smirnov distance (Figure 5C). The expression of HLA-DR, CD11b, CD45, CD64, CD39, CD14, CD86, and CD32, indicative of a highly activated state, was significantly stronger for monocytes belonging to the SQ-IM signature than to the MPLA signature. MPLA injected via the IM route induced DCs expressing lower levels of HLA-DR, CD39, CD123, and CD86, but higher levels of CD11c and CD16 than SQ injected via the same route (SQ-IM group). Finally, the SC route (MPLA-SC group) appears to differ from the IM route through high CADM1 expression.

In conclusion, each vaccine strategy induced a unique innate cell signature (Figure 5D), allowing to discriminate between vaccine regimens and adjuvants and defined by a combination of a small set of markers: HLA-DR, CD39, CD86, CD11b, CD45, CD64, CD14, CD32, CD11c, CD4, CD16, CD123, and CADM1.

Association of innate and adaptive immunity

We then investigated whether this set of markers could be used to predict the magnitude of the nAb response, IgG binding response, and Fc-mediated effector functions of IgGs (Figure 2). A generalized linear model constructed with KF abundances and antibody titers, neutralizing or FcγRIIa functions, measured 2 weeks after the second and third injection, was employed as predictive model (Figure 6).

Interestingly, three KFs for MPLA-IM (KF-II, III, and VII) and four for SQ-IM (KF-III, V, VII, and VIII) significantly correlated with nAb production (p < 0.05). KF-II, characterized by high expression of moDC and cDC2 markers (Figure 5D), was the family that most positively associated with high nAb titers for the MPLA-IM (Figure 6A). These cells are reported to display strong CD4+ T cell priming activity, notably for T helper 2 (Th2) cells, known to be involved in Ab responses. Consistently, this family was also positively associated with IgG binding titers for MPLA-SC and was not associated with IgG binding titers for MPLA-IM (Figure 6C). KF-III composed of HLA-DR0−CD11c−CD16+ DC was negatively associated to nAb production (p = 0.004) but was positively associated with rsFcγRIIa binding activity along with KF-V (Figure 6E).

For the SQ-IM group, and in marked contrast to MPLA-IM, the model positively associated KF-III with the nAb titer (Figure 6A) and monocytes from KF-I with rsFcγRIIa binding activity (Figure 6E). KF-VII, presumably composed of macrophage populations based on secondary markers expression, was also positively associated with nAb production, IgG, and rsFcγRIIa binding activities (Figures 6A, 6C, and 6E, respectively) for the SQ-IM group. Two KFs were negatively associated with SQ-IM nAb titers, both sharing similar features. Indeed, KF-V and KF-VIII both showed high CADM1 expression, mostly attributed to the cDC1 phenotype and cytotoxic response (Figure 6A). The CADM1+ cells of KF-V were HLA-DR0−CD11c−CD16+ , implying a cDC1 phenotype, whereas cells belonging to KF-VIII showed the opposite pattern of HLA-DR0−CD11c+CD16+ expression, characteristic of cDC1-like cells (Figure 5D). CADM1+ cells from KF-VIII were also negatively associated with IgG binding for both MPLA-SC and SQ-IM group and with rsFcγRIIa for all three groups (Figures 6C and 6E).

The robustness and accuracy of the model were confirmed by correlating predicted and observed values for every immune parameter studied (Figures 6B, 6D, and 6F). The observed nAb titers strongly correlated with those predicted by the model for both the MPLA-IM and SQ-IM vaccine strategies (r = 0.97 and r = 0.9, respectively). A strong correlation of IgG binding titers was also found for SQ-IM and MPLA-SC (r = 0.89 and r = 0.92, respectively) (Figure 6D) as well as MPLA-IM and SQ-IM with rsFcγRIIa binding activity (r = 0.9 and r = 0.75, respectively) (Figure 6F). However, no reliable prediction could be made regarding MPLA-SC nAb titers and rsFcγRIIa binding activity because they were only observed at low level after the third injection and not in all individuals.

These results demonstrate the ability of our model to predict humoral response, including IgG binding titers, nAb activity, and FcγRIIa engagement, through the characterization of innate cell populations as early as 1 day after vaccine injections.

DISCUSSION

Vaccine parameters, such as adjuvant and administration route, strongly influence the quality of the innate immune response and, ultimately, the adaptive immune response.18–22 NHPs are particularly relevant for such translational immunology studies because of the high similarity between the organization of the macaque and human immune systems. Here, we demonstrate in NHPs that it is possible to anticipate the quality of specific antibody responses based solely on the early innate response. We show that autologous ConM SOSIP.v7-specific IgG binding titers, nAb

**Figure 4. Follow-up of monocytes and dendritic cells population enrichment**

The pie charts show the average phenotypic family cell abundance between immunization groups within the monocyte and dendritic cell compartments (A). Phenotypic families are represented using the same colors and numbers as in Figure 3. The cell numbers correlate with the size of the segments in the pie charts and are given as 10^6 cells per mL of blood.

(B) Mean cell abundances dynamic and SD from the top three phenotypic families that display the most significant variations over the different time points. p values for the changes are presented in Table S1 and the fold change in Figure S5.
production, and rFcγRlla binding activity are induced more efficiently by the IM than the SC route when considering MPLA. However, the nAb responses induced by ConM SOSIP.v7 decayed quickly, which is consistent with many previous observations using HIV-1 Env-based vaccines, including gp120s and SOSIP trimers. 

There are reported evidences that early events following vaccine injections affecting APC targeting, activation, and antigen processing and presentation impact the quality of adaptive response. Indeed, Schifanella et al. reported in the NHP model that “The relationship between vaccine efficacy and the neutralization profile of the challenge virus appear to be linked to the different immunological spaces created by MF59 and Alum via CXCL10 and IL-1β, respectively.” suggesting a role for innate cells in the quality of induced nAb. This study confirms observations of the same group of authors who demonstrated that “Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-dependent mucosal innate immunity.”
lymphoid cells (ILCs) that produce interleukin (IL)-17, as well as with mucosal IgG to the gp120 variable region 2 (V2) and the expression of 12 genes, ten of which are part of the RAS pathway. 27 Similarly, the route of administration, and therefore the type of locally targeted APC, has been described as an important factor driving the quality of the neutralizing response against an SOSIP protein. Pauthner et al. demonstrated that subcutaneous immunizations induce stronger nAb responses against tier-2 HIV than intramuscular immunizations. Contrary to this study, we demonstrated that intramuscular immunizations elicit higher nAb responses against the SOSIP protein. The use of ISCOMATRIX as adjuvant by Pauthner et al. may lead to a different APC targeting, activation, and antigen processing and presentation then generating different nAb responses from what we observed.

Our results suggest that MPLA mainly affects the expansion of monocyte, mDC, and HLA-DRβ1-CD11c+CD16+ DC populations, especially when combined with the IM route. This may reflect adjuvants’ properties to mobilize immune cells into tissues as shown in mice with MF59, an oil in water emulsion similar to SQ. 28 Nevertheless, adjuvants alone could not explain the differences we observed. Indeed, the quality of innate immune responses is also dependent on innate cells tissues colonization, as previously reported. 22 Ols et al. 29 showed that an IM injection induced a greater antigen uptake by antigen-presenting cells than an SC injection of Env proteins in MPLA liposomes. They hypothesized that this may be due to a better formation of immune complexes when subjects are re-exposed because of the high vascularization of muscles. Such an effect, combined with the increasing number of circulating moDCs and HLA-DRβ1-CD11c+CD16+ DCs following ConM SOSIP. v7 immunization, could explain the higher nAb titers we observed following IM injections. Strikingly, the later monocyte activation and higher proportion of CADM1+ cells observed for the MPLA-SC compared with the other vaccine strategies may also be involved in the delayed nAb production observed in this group.

The dynamic changes observed for HLA-DRβ1-CD11c+CD16+ DCs following the MPLA-IM injections may also be associated with the properties of the tissue, as we previously showed a higher proportion of CD11c+ DC infiltration in the muscle than

---

Figure 6. The abundance of innate immune cell populations predicts ConM SOSIP.v7 humoral responses

A linear regression was employed to assess the relationship of the kinetic family cell abundance 24 h after the second and third injections with three biological outcomes: the nAb titer (A), the IgG binding titer (C), and the rsFcγRIIIa binding activity (E). MPLA-IM, MPLA-SC, and SQ-IM are displayed in red, green, and blue respectively. Linear regression coefficients with a p value ≤ 0.05 are considered necessary and sufficient to predict those humoral parameters. Iterative linear regressions were generated until all coefficients had a p value ≤ 0.05. (B, D, and F) represent the correlation of the observed and predicted values by the linear regression for nAb titer, IgG binding titer and the rsFcγRIIIa binding activity, respectively. The Pearson correlation coefficient and p values are shown.
in the skin following an SC modified vaccinia Ankara (MVA) vaccine injection. 22

The panel we used lacked antigen targeting receptors to address the antigen presentation capacities of DC, but the vaccine-induced signatures on all other markers and prediction analysis we performed may indeed help to speculate on DCs functionalities. In our study, cDC2 was identified as the SQ-IM vaccine group signature and was also positively associated with nAb production for MPLA-IM vaccine. However, the low abundance of variations detected suggests that cDC2 alone may not be the only APC implicated in the functional outcomes. The PF15 and PF25, identified as moDCs— known to have potent antigen presentation capacities—were also strongly mobilized by MPLA-IM and SQ-IM vaccines. Highly activated moDCs from PF2 were also recruited by the two groups and the SQ-IM group in particular. In addition to its similarity of phenotypic profile with cDC2, moDC expresses DC-SIGN and the macrophage mannose receptor, two receptors implicated with antigen sensing and induction of Th2 responses and then able to drive immune response toward antibodies production. 30

Noteworthy, studies on antigen delivery in mice demonstrated that targeting CD11c led to the induction of strong CD4+ and CD8+ T cells response in addition to strong antibody responses. 31, 32 The CD11c+ DC subsets abundance we observed suggests its key role in vaccine response orientation. This may be particularly true for MPLA-IM group where some of CD11c+ DC kinetics families (KF-III) constitute the vaccine signature.

On the other hand, the MPLA-SC group can be discriminated from the two other route/adjuvant combinations based on CADM1 expression by cDC1, which is classically associated with CD8+ T cells and Th1 priming. In addition, cDC1 subsets we identified also express Clec9A, a C-type lectin receptor known for its implication in the generation of cytotoxic CD8 T cell responses. We may thus speculate that if not optimal for antibody production, this adjuvant/route combination would be of interest for promoting cellular immunity. The key role of CADM1 in vaccine response orientation is conferred by the negative association we observed for this marker with MPLA-IM and SQ-IM in induced antibody responses. FcγRIIa and FcγRIIIb, two isoforms of CD16, have been associated with innate cell cytotoxicity. 33 Monocytes are known to express CD16, and although CD16+ DCs remain a controversial subset, Fromm et al. 34 demonstrated that CD16+ monocytes and CD16+ DCs were two phenotypically and functionally distinguishable populations that have been identified to be able to perform ADCC. 35, 36 Our data show an important mobilization of monocytes and CD16+ DCs in the blood of all animals, and especially for the MPLA-IM group. However, a greater rsFcγRIIIa binding activity was observed in the SQ-IM vaccinated animals, where those populations were less represented. This suggests that rsFcγRIIIa binding activity may not be exclusively explained by monocytes and CD16+ DCs recruitment. Indeed, other CD16+ innate populations, such as neutrophils and NK cells, known to exert cytotoxic activity, might have been underestimated in our study. 37 We recently reported that polymorphonuclear (PMN) cells, in particular, are key players in vaccine responses. 38, 39 Unfortunately, granulocytes were unexplored in our study because of technical limitations. Future studies should assess the value of integrating PMN and NK markers in such kind of analysis, in order to correlate these populations to rsFcγRIIIa binding activity and thus more finely predict vaccine responses.

In addition to PMN and NK cells, using similar approaches for the study of B and T lymphocytes, including antigen-specific cells, would be of interest to characterize the installation of vaccine response, as it has been shown that increased antibody responses depend on enhanced interactions between APCs and CD4+ T cells and B cells.

In the field of HIV vaccines, an important role of myeloid cell-expressing markers was also identified in our NHP study. Indeed, in a human systems vaccinology approach of the ALVAC-HIV vaccine, Andersen-Nissen and colleague observed an enrichment of monocytes and CD16+ monocytes-associated transcripts. 40 Also, NHP studies based on the ALVAC-SIV have associated monocytes signatures with a decreased risk of SIV-mac251 acquisition. 37, 38 In our manuscript, we also highlighted an important role of monocytes following the different vaccines including CD16+ non-classical and intermediate monocytes, especially for animals immunized with the HIV glycoprotein in MPLA adjuvant and by IM route. Furthermore, we also evidenced a role for CD11c+CD16+ DCs that was not mentioned in these previous studies.

It is possible that the changes in cell populations we observed in the cynomolgus macaque model may be of interest in the design and monitoring of vaccine responses in humans, although species specificities in immune cell compartments need to be considered when transferring knowledge from animal studies to clinical trials. 42–44

In conclusion, we show that autologous Ab binding titers and neutralizing activity are induced more efficiently by the IM than SC route when MPLA is used as adjuvant and that the efficacy of MPLA and SQ is in the same range when the IM route is used, even though immune pathways involved seem to differ. We also reveal an association between early-occurring myeloid cell signatures following immunization and adaptive immune parameters. These findings provide new insights on immune mechanisms of interest for vaccine innovation and demonstrate that monitoring of innate signatures during early vaccine development could help minimizing the risk of failure during clinical development phases.

**Limitations of the study**

The results from this study may inform future strategies for evaluating the effectiveness of HIV-1 vaccines in preclinical animal models and humans. However, it is important to note that we lack data on autologous and heterologous tier-2 viruses’ neutralization, which represent a limitation in our study as the induction of bnAbs is expected to be required for an effective HIV vaccine.

While rhesus macaques have been used for many HIV vaccine studies, we and others have extensively used cynomolgus macaques for assessing host immune response to SIV/SHIV infection and to HIV vaccines. 45–49 A direct comparison of both species should reveal if any of these models is more representative for human responses. However, most antibodies used to phenotype cluster determinants and to characterize cytokine production are anti-human determinant antibodies selected to cross-react with macaque determinants. As a consequence,
reagents availability represents a technical limitation that drives panel design, and some markers classically used to characterize cell populations in humans may not be available for NHPs. Furthermore, anti-human antibodies may result in slightly altered signal detection in flow and mass cytometry due to differences in binding affinity on macaque epitopes. Finally, markers expression may differ between species as some of them might be specific to a given species. Furthermore, a given marker expressed in both human and macaque may not be identified in the same cell population, thus limiting the full translation of the preclinical studies to the human situation.\textsuperscript{10}

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Ethics and biosafety statement
  - Animals and study design
  - Adjuvants
- **METHOD DETAILS**
  - ELISA reagents and procedures
  - Neutralization assay
  - ELISA-based rsFcγRIIa dimer-binding assay
  - Antibody coupling with lanthanide isotopes
  - Staining and CyTOF acquisition
  - Data processing
  - Cell population identification
  - Heatmap representation
  - Phenotypic and kinetic families
  - Negative-stain electron microscopy
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Statistics
  - Linear discriminant analysis
  - Cytopcompare
  - Generalized linear model

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2022.100751.

ACKNOWLEDGMENTS

We thank the staff of the animal facility of IDMIT, particularly B. Delache, M. Pottier, S. Langlois, J.M. Robert, N. Dhooge, and R. Ho Tsong Fang. We also thank S. Kent, M. Hogarth, and B. Wines for providing the dimeric FcγRIIa protein. Dietmar Katinger provided the adjuvants. This study was supported by the European Union’s Horizon 2020 (EAVI2020, grant N° 681137), the European Infrastructure TRANSVAC2 (grant N° 730964), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS) and the Bill and Melinda Gates Foundation (OPP115782), R.W.S. is a recipient of a Vici fellowship from the Netherlands Organisation for Scientific Research (NWO). The Infectious Disease Models and Innovative Therapies Research Infrastructure (IDMIT) is supported by the “Programmes Investissements d’Avenir” (PIA), managed by the ANR under references ANR-11-INBS-0008 and ANR-10-EQPX-02-01. J.L.P. received a PhD scholarship from the University of Paris-Saclay. We thank the Fondation Doremeur Vaduz for the donation of instruments relevant to this project.

AUTHOR CONTRIBUTIONS

A.B.W. and O.G. and performed electron microscopy experiments. A.S.B. contributed to the mass cytometry experiments design. A.S.G. coordinated the cytometry platform and experiments. E.G. contributed to the data analysis. E.M.L. managed the mass cytometer and contributed to the results analysis. G.S. contributed to the design of the study and the analysis of the data and coordinated the neutralization assays. I.B. designed and produced the immunogens. J.L.P. designed and supervised the mass cytometry experiments and contributed to the data analysis. M.C. coordinated the FcγR-binding assays and contributed to analysis of the data. M.T. performed the neutralization assays and analysis. M.V.T. performed the mass cytometry experiments, analyzed the data, and wrote the article. N.D.B. managed the ethical authorizations, prepared the vaccines, and contributed to the study design, to coordination, and to the data analyses. P.M. contributed to the design of the study, coordinated the study and experiments, prepared the vaccines, and contributed to the data analysis. P.M.K. supervised the ELISA experiments. R.L.G. contributed to the study design and the results analysis. R.J.S. coordinated the EAVI2020 project and contributed to the study design and to the results analysis. R.S. contributed to the study design and coordinated the immunogens production. Y.A. performed and analyzed the ELISA. All authors reviewed and edited the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 24, 2021
Revised: June 9, 2022
Accepted: September 2, 2022
Published: September 26, 2022

REFERENCES

1. United Nations Joint Programme on HIV/AIDS (UNAIDS) (2019). UNAIDS Data 2019, p. 476.
2. Gaucher, D., Therrien, R., Ketfâ, N., Angermann, B.R., Boucher, G., Filali-Mouhim, A., Moser, J.M., Mehta, R.S., Drake, D.R., 3rd, Castro, E., et al. (2008). Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205, 3119–3131.
3. Querec, T.D., Akondy, R.S., Lee, E.K., Cao, W., Nakaya, H.I., Teuwen, D., Pirani, A., Genert, K., Deng, J., Marzolf, B., et al. (2009). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116–125.
4. Hou, J., Wang, S., Jia, M., Li, D., Liu, Y., Li, Z., Zhu, H., Xu, H., Sun, M., Lu, L., et al. (2017). A systems vaccinology approach reveals temporal transcriptomic changes of immune responses to the yellow fever 17D vaccine. J. Immunol. 199, 1476–1489.
5. Rechtien, A., Richert, L., Lorenzo, H., Martrus, G., Heiblum, B., Dahlke, C., Kasonta, R., Zinser, M., Stubbe, H., Matschlf, U., et al. (2017). Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the ebola vaccine rVSV-ZEBOV. Cell Rep. 20, 2251–2261.
6. Li, S., Roupaha, N., Durasingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D.S., Johnson, S.E., Milton, A., Rajam, G., et al. (2014). Molecular signatures of antibody responses derived from a systematic biology study of five human vaccines. Nat. Immunol. 15, 195–204.
7. Nakaya, H.I., Clutterbuck, E., Kazmin, D., Wang, L., Cortese, M., Bosinger, S.E., Patel, N.B., Zak, D.E., Aderem, A., Dong, T., et al. (2018). Systems
biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc. Natl. Acad. Sci. USA 113, 1853–1858.

8. Tsang, J.S., Schwartzberg, P.L., Kotiarov, Y., Biancotto, A., Xie, Z., Germain, R.N., Wang, E., Olnes, M.J., Narayanan, M., Goldberg, H., et al. (2014). Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 157, 499–515.

9. Trautmann, L., and Sekaly, R.P. (2011). Solving vaccine mysteries: a systems biology perspective. Nat. Immunol. 12, 729–731.

10. Mooney, M., McWeeney, S., Canderan, G., and Sekaly, R.P. (2013). A systems framework for vaccine design. Curr. Opin. Immunol. 25, 551–555.

11. Reimann, K.A., Parker, R.A., Seaman, M.S., Beaudry, K., Beddall, M., Peterson, L., Williams, K.C., Vezays, R.S., Montefiori, D.C., Mascola, J.R., et al. (2005). Pathogenesis of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J. Virol. 79, 8878–8885.

12. Este, J.D., Wong, S.W., and Brenchley, J.M. (2018). Nonhuman primate models of human viral infections. Nat. Rev. Immunol. 18, 390–404.

13. Sanders, R.W., and Moore, J.P. (2017). Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol. Rev. 275, 161–182. doi:10.1111/imr.12481.

14. De Taeye, S.W., Ozorowski, G., de la Peña, A.T., Gutmann, M., Julien, J.-P., van den Kerkhof, T.L.G.M., Burger, J.A., Pritchard, L.K., Pugach, P., Yamaite, A., et al. (2015). Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell. https://doi.org/10.1016/j.cell.2015.11.056.

15. Sliepen, K., Han, B.W., Bontjer, I., Mooij, P., Garces, F., Behrens, A.J., Sliepen, K., Han, B.W., Bontjer, I., Mooij, P., Garces, F., Behrens, A.J., et al. (2019). Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nat. Commun. 10, 2355.

16. Brouwer, P.J.M., Antanasijevic, A., Berndsen, Z., Yasmeen, A., De Gregorio, E., O’Hagan, D., Rappuoli, R., and De Gregorio, E. (2008). Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. USA 105, 10501–10506.

17. Ols, S., Yang, L., Thompson, E.A., Pushparaj, P., Tran, K., Liang, F., Lin, A., Eriksson, B., Karlsson Hedestam, G.B., Wyatt, R.T., and Lör, K. (2020). Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity. Cell Rep. 30, 3964–3971.e7.

18. Lehmann, C.H.K., Heger, L., Heidkamp, G.F., Banarska, A., Lühr, J.J., Hoffmann, A., and Duddia, D. (2016). Direct delivery of antigens to dendritic cells via antibodies specific for endocytic receptors as a promising strategy for future therapies. Vaccines 4, 8.

19. Castro, F.V.V., Tutt, A.L., White, A.L., Teeling, J.L., James, S., French, R.R., and Glennie, M.J. (2008). CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur. J. Immunol. 38, 2263–2273.

20. White, A.L., Tutt, A.L., James, S., Wilkinson, K.A., Castro, F.V.V., Dixon, S.V., et al. (2010). Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant. Immunology 131, 141–151.

21. Zhang, Y., Boesen, C.C., Radaev, S., Brooks, A.G., Fildman, W.H., Sautes-Fridman, C., and Sun, P.D. (2000). Crystal structure of the extracellular domain of a human Fc receptor. J. Mol. Biol. 297, 3363–3368.

22. Pauwheer, M., Rovan-Daughton, C., Xie, Z., Nikolova, J.P., Béristaud, R., Boopathy, A.V., Camathian, D.G., Chandrashekar, A., Cirelli, K.M., Cottrell, C.A., et al. (2017). Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. Immunity 46, 1073–1088.e6.

23. O’Hagan, D.T., Ott, G.S., De Gregorio, E., and Seubert, A. (2012). The mechanism of action of MF59—an intratelymphatic adjuvant formulation. Vaccine 30, 4341–4348.

24. Rosenbaum, P., Tchitchek, N., Joly, C., Rodriguez Pozo, A., Stimmer, L., Langlois, S., Hocini, H., Gosses, L., Pejoski, D., Cosma, A., et al. (2020). Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response. SSRN J. https://doi.org/10.2139/ssrn.3935877.

25. Anderson, K.P., Lucas, C., Hanson, C.V., Londe, H.F., Izu, A., Gregory, T., Ammann, A., Berman, P.W., and Eichberg, J.W. (1988). Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J. Infect. Dis. 160, 960–969.

26. Sanders, R.W., van Gils, M.J., Derking, R., Sok, D., Ketas, T.J., Burger, J.A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. (2015). HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223.

27. Brouwer, P.J.M., Antanasijevic, A., de Gast, M., Allen, J.D., Bijl, T.P.L., Yasmeen, A., Ravichandran, R., Burger, J.A., Ozorowski, G., Torres, J.L., et al. (2021). Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ Vaccines 6, 24.

28. Schifanella, L., Bennett, S.W., Bissa, M., Galli, V., Doster, M.N., Vaccari, M., Tomaras, G.D., Shen, X., Phogat, S., Pal, R., et al. (2019). ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. PLoS Pathog. 15, e1008121.

29. Vaccari, M., Fourati, S., Gordon, S.N., Brown, D.R., Bissa, M., Schifanella, L., Silva de Castro, I., Doster, M.N., Galli, V., Omsland, M., et al. (2018). HIV vaccine candidate activation of hyposym and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat. Med. 24, 847–856.

30. Mosca, F., Titto, E., Muzzi, A., Monaci, E., Bagnoi, F., Iavaron, C., O’Hagan, D., Rappuoli, R., and De Gregorio, E. (2008). Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. USA 105, 10501–10506.
Cell Reports Medicine

Lévy, Y., et al. (2020). Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. NPJ Vaccines 5, 24.

40. Andersen-Nissen, E., Fiore-Gartland, A., Ballweber Fleming, L., Carpp, L.N., Naidoo, A.F., Harper, M.S., Voillet, V., Grunenberg, N., Laher, F., Innes, C., et al. (2021). Innate immune signatures to a partially- efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathog. 17, e1009363.

41. Gorini, G., Fourati, S., Vaccari, M., Rahman, M.A., Gordon, S.N., Brown, D.R., Law, L., Chang, J., Green, R., Barrenas, F., et al. (2020). Engagement of monocytes, NK cells, and CD4+ T cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. PLoS Pathog. 16, e1008377.

42. Autissier, P., Soulas, C., Burdo, T.H., and Williams, K.C. (2010). Immuno-phenotyping of lymphocyte, monocyte and dendritic cell subsets in normal rhesus macaques by 12-color flow cytometry: clarification on DC heterogeneity. J. Immunol. Methods 360, 119–128.

43. Sugimoto, C., Hasegawa, A., Saito, Y., Fukuyo, Y., Chiu, K.B., Cai, Y., Breed, M.W., Mori, K., Roy, C.J., Lackner, A.A., et al. (2015). Differentiation kinetics of blood monocytes and dendritic cells in macaques: insights to understanding human myeloid cell development. J. Immunol. 195, 1774–1781.

44. Elhmouzi-Younes, J., Palgen, J.L., Tchitchek, N., Delandre, S., Namet, I., Cavarelli, M., Hua, S., Hantour, N., Tricot, S., Tchitchek, N., Gommet, C., Le Grand, R., Dereuddre-Bosquet, N., Dispinseri, S., Gosse, L., Desjardins, B., Lemaitre, J., Desjardins, D., Galloueft, A.S., Gomez-Pacheco, M., Bour-ferron, A., Machuca, A., Levallois, A., Marquet, A., Poyet, A., et al. (2018). Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry. Nat. Protoc. 13, 2121–2148.

45. Finck, R., Simonds, E.F., Jager, A., Krishnaswamy, S., Sachs, K., Fanti, W., Pe’er, D., Nolan, G.P., and Bendall, S.C. (2013). Normalization of mass cytometry data with bead standards. Cytometry A. 83, 485–494.

46. Kleinsteuber, K., Corleis, B., Rashidi, N., Nhinda, N., Lisanti, A., Cho, J.J., Medoff, D.B., Kwon, D., and Walker, B.D. (2016). Standardization and quality control for high-dimensional mass cytometry studies of human samples. Cytometry A. 89, 903–913.

47. Liu, P., Simonds, E.F., Bendall, S.C., Gibbs, K.D., Jr., Bruggner, R.V., Linderman, M.D., Sachs, K., Nolan, G.P., and Plevritis, S.K. (2011). Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat. Biotechnol. 29, 886–891.

48. Gautreau, G., Pejoski, D., Le Grand, R., Cosma, A., Beignon, A.S., and Tchitchek, N. (2017). SPADEviZr: an R package for visualization, analysis and integration of SPADE results. Bioinformatics 33, 779–781. https://doi.org/10.1093/bioinformatics/btw708.

49. Suloway, C., Pulokas, J., Fellmann, D., Cheng, A., Guerra, F., Quispe, J., Stagg, S., Potter, C.S., and Carragher, B. (2005). Automated molecular microscopy: the new Legion system. J. Struct. Biol. 151, 41–60.

50. Lander, G.C., Stagg, S.M., Voss, N.R., Cheng, A., Fellmann, D., Pulokas, J., Yoshioka, C., Irving, C., Mulder, A., Lau, P.W., et al. (2009). Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95–102.

51. Pugach, P., Ozorowski, G., Cupo, A., Ringe, R., Yasmene, A., de Val, N., Derking, B., Kim, H.J., Korzun, J., Golabek, M., et al. (2015). A native-like SOSIP.644 trimmer based on an HIV-1 subtype B Env gene. J. Virol. 89, 3380–3395.

52. Sanders, R.W., Derking, R., Cupo, A., Julien, J.P., Yasmene, A., de Val, N., Kim, H.J., Blattner, C., de la Peña, A.T., Korzun, J., et al. (2013). A next-generation cleaved, soluble HIV-1 env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618.

53. Platon, L., Pejoski, D., Gautreau, G., Targat, B., Le Grand, R., Beignon, A.S., and Tchitchek, N. (2018). A computational approach for phenotypic comparisons of cell populations in high-dimensional cytometry data. Methods 132, 66–75.
## STAR Methods

### Key Resources Table

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| CD66abc Antibody, anti-human | Miltenyi Biotec | Custom reagent (TET2) |
| Purified anti-human HLA-DR Antibody | Biolegend | Cat#307612; RRID:AB_314690 |
| BD Pharmingen™ Purified mouse anti-human CD3 | BD Biosciences | Cat#551916; RRID:AB_394293 |
| CD64 Antibody, anti-human | Miltenyi Biotec | Custom reagent (TET2) |
| BD Pharmingen™ Purified mouse anti-human CD8 | BD Biosciences | Cat#555364; RRID:AB_395767 |
| IL-6 Antibody, anti-human | Miltenyi Biotec | Cat#130-096-093; RRID:AB_2652449 |
| BD Pharmingen™ Purified Mouse Anti-Human CD123 | BD Biosciences | Cat#554527; RRID:AB_395455 |
| BD Pharmingen™ Purified Mouse Anti-Human IL-4 | BD Biosciences | Cat#554515; RRID:AB_398567 |
| CD11a Antibody, anti-human | Miltenyi Biotec | Custom reagent (HI111) |
| BD Pharmingen™ Purified Mouse Anti-Human CD11b | BD Biosciences | Cat#555386; RRID:AB_395787 |
| CD62L Antibody, anti-human | Miltenyi Biotec | Custom reagent (SK11) |
| BD Pharmingen™ Purified Mouse Anti-Human CD4 | BD Biosciences | Cat#550625; RRID:AB_393787 |
| Anti-human FceRI Prufied | eBioscience | 14-5899-82 |
| BD Pharmingen™ Purified Mouse Anti-Human CD86 | BD Biosciences | Cat#55663; RRID:AB_396017 |
| CD172a Antibody, anti-human | Miltenyi Biotec | Custom reagent (15–414/REA144 ; RRID:AB_2801909) |
| IP-10 Antibody, anti-human | Miltenyi Biotec | Cat#130-108-047 ; RRID:AB_2651479 |
| BD Pharmingen™ Purified Mouse Anti-Human CD45 | BD Biosciences | Cat#552566; RRID:AB_394433 |
| IL-1a Antibody, anti-human | Miltenyi Biotec | Custom reagent (364-3B3–14) |
| Anti-hCD1c Affinity Purified Goat IgG | R&D systems | Cat# AF5910; RRID:AB_1964521 |
| IL-12 Antibody, anti-human | Miltenyi Biotec | Custom reagent (C8.6 ; RRID:AB_10829623) |
| BD Pharmingen™ Purified Mouse Anti-Human CD32 | BD Biosciences | Cat#555447; RRID:AB_395840 |
| IFNa Antibody, anti-human | Miltenyi Biotec | 130-108-050; RRID:AB_2659989 |
| Purified anti-human CD39 (MaxPar® Ready) | Biolegend | Cat#328221; RRID:AB_2563747 |
| BD Pharmingen™ Purified Mouse Anti-Human CD195 (CCR5) | BD Biosciences | Cat# 556041; RRID:AB_396312 |
| CD16 Antibody, anti-human | Miltenyi Biotec | 130-108-027 ; RRID:AB_2655423 |
| Purified anti-human CD11c (MaxPar® Ready) | Biolegend | Cat#301639; RRID:AB_2562812 |
| BD Pharmingen™ Purified Mouse Anti-Human CD184 (CXCR4) | BD Biosciences | Cat#555972; RRID:AB_396265 |
| BD Pharmingen™ Purified Mouse Anti-Human CD14 | BD Biosciences | Cat#555396; RRID:AB_395797 |
| BD Pharmingen™ Purified Mouse Anti-Human IL-8 | BD Biosciences | Cat#554717; RRID:AB_398583 |
| Mouse anti-human CD23 | Beckman Coulter | IMBULK1 |
| BD Pharmingen™ Purified Mouse Anti-Human CD141 | BD Biosciences | Cat#559780; RRID:AB_397321 |
| BD Pharmingen™ Purified Mouse Anti-Human CD20 | BD Biosciences | Cat#556631; RRID:AB_396500 |
| CCR7 Antibody, anti-human | Miltenyi Biotec | Custom reagent (G043H7) |
| Anti-SynCAM (TSLC1/CADM1) | MBL | Cat# CM004-3; RRID:AB_592783 |
| Goat anti-Monkey IgG horseradish peroxidase labelled | AbSerotec | AA42P |

### Biological samples

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Cynomolgus macaques PBMCs | IDMIT facility, CEA de Fontenay-aux-roses, France | N/A |
| Cynomolgus macaques serum | IDMIT facility, CEA de Fontenay-aux-roses, France | N/A |

(Continued on next page)
Continued

### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Chemicals, peptides, and recombinant proteins** | | |
| Maxpar® X8 Antibody Labelling Kit, Tag-141Pr to 176Yb | Fluidigm | 201141A to 201176A |
| Cell-ID™ Intercalator-Ir—500 µM | Fluidigm | 201192B |
| Cell-ID™ Intercalator-Rh—2000 µM | Fluidigm | 201103B |
| ConM SOSIP.v7 protein | Rogier Sanders (Sliepen et al., 2019) | https://doi.org/10.1038/s41467-019-10262-5 |
| Mono Phosphoryl Lipid A (MPLA adjuvant) | Polymun Scientific (Klosterneuburg, Austria) | N/A |
| Squalen Emulsion (SQ adjuvant) | Polymun Scientific (Klosterneuburg, Austria) | N/A |
| BSA cat#A7906-1kg | Sigma Aldrich | SLBS4333 |
| Purified dimeric macaque rsFcγRIIIa Ile158 ectodomain biotin | Hogarth laboratory | N/A |
| Ultra streptavidin HRP | Thermo Scientific | cat# N504 |
| TMB | Thermo Scientific | cat# 34028-250mL |
| HCL 1N | VWR | MC3006470500 |
| EDTA | Sigma Aldrich | cat# E5391-250g |
| Tween 20 | Sigma Aldrich | cat# P7949-100mL |
| SOSIP antigens | Rogier Sanders Amsterdam University Medical Centers, Amsterdam Netherlands | N/A |
| Bright-Glo | Promega | Cat# E2620 |

### Experimental models: Cell lines

| EXPERIMENTAL MODEL | SOURCE | IDENTIFIER |
|-------------------|--------|------------|
| HEK293F cells | Invitrogen | R79009 |
| HEK-293T/17 | CFAR-NIBSC, UK | Cat# 5016 |
| TZM-bl | CFAR-NIBSC, UK | Cat#ARP5011 |

### Experimental models: Organisms/strains

| EXPERIMENTAL MODEL | SOURCE | IDENTIFIER |
|-------------------|--------|------------|
| Cynomolgus macaques: Macaca fascicularis | AAALAC certified breeding centers | N/A |

### Recombinant DNA

| EXPERIMENTAL MODEL | SOURCE | IDENTIFIER |
|-------------------|--------|------------|
| HIV-1 backbone pSG3 ΔEnv | David C. Montefiori Duke Human Vaccine Institute and Center for HIV-AIDS Vaccine Immunology, Duke University Medical Center, Durham, NC, USA | N/A |
| pSVIII-93MW 965.26 | CFAR-NIBSC, UK | Cat# 2073 |
| pConM SOSIP.v7 HIV-1 | Rogier Sanders Amsterdam University Medical Centers, Amsterdam Netherlands | N/A |

### Software and algorithms

| SOFTWARE AND ALGORITHMS | SOURCE | IDENTIFIER |
|-------------------------|--------|------------|
| MatLab compiler software | Beckman Coulter | N/A |
| CyTOF software | Fluidigm | N/A |
| Cytobank Premium | Beckman Coulter | N/A |
| R software | | N/A |
| SPADEVizR R package | https://github.com/tchitchek-lab/SPADEVizR | N/A |
| “MASS” R package | https://CRAN.R-project.org/package=MASS | N/A |
| Leginon | (Suloway et al., 2005) | https://nramm.nysbc.org/software; RRID:SCR_016731 |
| Appion | (Lander et al., 2009) | https://nramm.nysbc.org/software; RRID:SCR_016734 |

(Continued on next page)
RESOURCES AVAILABILITY

LEAD CONTACT

Correspondence and requests for materials should be addressed to Roger Le Grand (roger.le-grand@cea.fr).

MATERIALS AVAILABILITY

This study did not generate new unique reagents. Requests for materials will require specific agreements and should be addressed to the lead contact, Roger Le Grand.

DATA AND CODE AVAILABILITY

The data that support the findings of this study are available from the corresponding author upon reasonable request. This paper does not report original code. Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

ETHICS AND BIOSAFETY STATEMENT

Cynomolgus macaques (Macaca fascicularis) originating from Mauritius and imported from AAALAC certified breeding centers were used in this study. All animals were housed in groups at the IDMIT infrastructure facilities (CEA, Fontenay-aux-roses, Animal facility authorization #D92-032-02, Prefecture des Hauts de Seine, France) and in compliance with European Directive 2010/63/EU, the French regulations, and the Standards for Humane Care and Use of Laboratory Animals, of the Office for Laboratory Animal Welfare (OLAW, assurance number #A5826-01, US). The protocols were approved by the institutional ethical committee “Comité d’Ethique en Expérimentation Animale du Commissariat à l’Energie Atomique et aux Energies Alternatives » (CEtEA #44) under statement number A15-073. The study was authorized by the “Research, Innovation and Education Ministry” under registration number APA-FIS#3132–2015121014521340.

ANIMALS AND STUDY DESIGN

Eighteen adult, female cynomolgus macaques, aged 33 to 42 months, were randomly assigned to three experimental groups of six animals each. All animals were immunized at W0, W8, and W24 with 20 μg ConM SOSIP formulated either with 500 μg MPLA liposomes (MPLA) or 0.5 mL squalene emulsion (SQ). The vaccine was divided between each thigh. One group was immunized by the subcutaneous (SC) route with the MPLA regimen (MPLA-SC), one received the MPLA regimen by the intramuscular (IM) route (MPLA-IM), and the third group received the SQ by the IM route (SQ-IM).

Group size of animals has been defined accordingly to the primary end-point of the study aiming at identifying the best combination of route and adjuvant for generating neutralizing antibodies when comparing the means of the experimental groups. A level of significance of 5% (α = 0.05) and a target power of 80% (1 - β = 0.8) was established. As a consequence, the system biology approach we proposed for identification of early cellular markers predicting Nab response, was exploratory and the N was not defined accordingly to this secondary objective. However, the size of our experimental groups is in the range of similar previously published studies using NHP.

Animals were observed daily, and clinical exams were performed at baseline and at each bleeding, as described in Figure 1, on anesthetized animals using ketamine (5 mg.kg-1) and medetomidine (0.042 mg.kg-1). Body weight and rectal temperature were recorded, and blood was collected. Blood cell counts, hemoglobin levels, and the hematocrit were determined from EDTA blood using a HMX A/L analyzer (Beckman Coulter). ConM SOSIP.v7.

ConM SOSIP.v7 protein was expressed and purified as published previously. In brief, ConM SOSIP.v7 was expressed in transiently transfected HEK293F cells (Invitrogen, catalog number R79009) and purified from vacuum-filtered (0.2 μm filters) transfection supernatants by PGT145 bNab-affinity chromatography. The protein was verified by SDS-PAGE analysis and Blue native PAGE analysis as described.
Adjuvants
The MPLA liposomes and squalene emulsion were manufactured at Polymun Scientific (Klosterneuburg, Austria). MPLA batch number MPLA/L02/0.2 µm-filtered was mixed extemporaneously at 500 µg/mL with 20 µg SOSIP in PBS to 1 mL. Squalene emulsion batch IMP/300916/10.22-µm filtered was composed of an oil phase (5% v/v squalene and 0.5% w/v Span 85) in an aqueous phase (0.5% w/v Tween 80) and 0.5 mL was mixed with 20 µg SOSIP extemporaneously in PBS to 1 mL.

METHOD DETAILS

ELISA reagents and procedures
Antigen-specific IgG levels were assessed by capture ELISA using Myc-c tagged ConM SOSIP.664 v7 for capture by monoclonal Ab 9E10 (ATCC hybridoma). Nunc MaxiSorp high binding 96-well plates (Thermo Fisher Scientific) were coated with 2.5 µg/mL of 9E10 Ab in 100 µL/well 1x PBS. The last 3 columns of each plate were coated with goat anti-human Kappa and goat anti-human Lambda (Southern Biotech) for the captured standard IgG, 1:2,000 for each antibody in 100 µL/well 1x PBS. The plates were incubated overnight at +4 °C, washed 4 times with 350 µL/well 1x PBS-0.05% Tween 20, tapped dry and blocked 1 h at +37 °C with 200 µL/well casein buffer (Thermo Fisher Scientific). Following 4 washes, 1 µg/mL ConM SOSIP.664 v7 Myc-HIS trimers in 100 µL/well casein buffer were loaded onto the plates and standard wells with 100 µL/well CB without tagged protein. After a 1 h incubation at +37 °C, plates were washed again and diluted samples added in triplicate wells in 50 µL/well casein buffer (1:100, 1:1,000, 1:10,000 dilutions). The cynomolgus macaque IgG standard (Molecular Innovations) was serially diluted in casein buffer starting at 200 ng/mL (1:5 serial dilution) and then loaded onto the standard wells (50 µL/well). The plates were incubated at +37 °C for 1 h, washed and mouse anti-rhesus monkey IgG Fc biotinylated Ab (Southern Biotech) loaded using a 1:50,000 dilution in 100 µL/well casein buffer. Following another hour incubation at +37 °C and washing step, poly-HRP40 was loaded onto the wells at 1:10,000 dilution in casein buffer (100 µL/well). Finally, after 1 h at +37 °C, the plates were washed, tapped dry and developed for 5 min with 50 µL/well Sureblue TMB substrate and stopped with 50 µL/well Stop solution (KPL). A KC4 Spectrophotometer (BioTek) was used to read the absorbance at 450 nm and a 4-PL fit curve was used to determine the standard curves and the linear range where the appropriate sample dilution would fall into. Standard curves and raw data were interpolated in the SoftMax Pro software (Molecular Devices), exported as text files, analysed in Excel (Microsoft) and plotted in Prism v7.0 (GraphPad Software).

Neutralization assay
Env-pseudotyped virus (PSV) 93MW965.26 and infectious molecular clone (IMC) ConM15 were produced in HEK293T cells, tittered against VSV was used to exclude unspecific reactions. Neutralization titers were defined as the sample dilution at which RLU were reduced by 50% compared to virus control wells after subtraction of background RLU in control wells with only cells. Inhibitory concentrations 50 (IC50) were calculated with a linear interpolation method using the mean of the duplicate responses.53

ELISA-based rsFcγRIIIa dimer-binding assay
The protocol of the ELISA-based IgG assay using recombinant soluble FcγRIIIa dimer has been previously described.17,54 Briefly, ELISA plates (MaxiSorp plates; Nalgene Nunc, Rochester, NY) were coated overnight at 4 °C with ConM SOSIP.v7 protein diluted to 50 ng per well in PBS, as well as no Ag as a negative control. HIVIG (#3957; National Institutes of Health AIDS Reagent) was used at 5 µg/mL to normalize the results across all plates. Coated plates were subsequently washed with PBS containing 0.05% Tween 20 (Sigma Aldrich) (PBST) and blocked with blocking buffer, consisting of PBS containing 1 mM EDTA and 1% BSA (both from Sigma- Aldrich), for 1 h at 37 °C. Macaque sera were diluted 1/50 in blocking buffer and incubated for 1 h at 37 °C. After washing 5 times the plates with PBST, purified dimeric macaque rsFcγRIIIa-biotin (I158 allele) was added to the plate at a concentration of 0.1 µg/mL and the plates incubated for 1 h at 37 °C. Plates were washed again 5 times with PBST, before horseradish peroxidase (HRP)-conjugated streptavidin (Thermo Fisher Scientific) was added and the plates incubated for another 1 h at 37 °C. After washing, the color was developed using 3,3′, 5,5-tetramethylbenzidine (TMB) (Life Technologies), followed by the addition of 1 M HCl stop solution. The absorbance at a wavelength of 450 nm was recorded. The no-Ag values were subtracted from each Ag sample. The resulting absorbance values were multiplied by the serum dilution factor. A positive signal was defined as an absorbance higher than the mean +3 x SD of the one obtained using sera from macaques before immunization.

Antibody coupling with lanthanide isotopes
Four hundred micrograms of each antibody was conjugated to metals using MaxPar X8 conjugation kits (DVS Science) following the manufacturer’s instructions. Briefly, lanthanides were loaded onto the polymer and then purified by centrifugation through an AMICON 3-kDa filter (Merck Millipore). Antibodies were also purified using an AMICON 50-kDa filter and partially reduced by TCEP-R-Buffer before conjugation to the metal-loaded polymers.55 Following conjugation, antibodies were resuspended at
1 μg/μL in Candor PBS Antibody Stabilization solution (Candor Bioscience) with 0.05% sodium azide and stored at 4°C. All conjugated monoclonal Ab used for labeling are shown in Table S3. The same batch of Ab were used for the different timepoints.

**Staining and CyTOF acquisition**
Whole blood was collected in heparin/lithium tubes and cryopreserved in 10% FCS/DMSO. Samples were rapidly thawed, washed with RPMI medium, and then incubated in RPMI supplemented with 10 mg/mL DNase for 30 min at 37°C. Cells were then resuspended in 1 x PBS and incubated for 15 min at 37°C with 1 μL Intercalator-Rh (DVS Sciences). After washing in PBS-0.5% BSA, cells were stained for 30 min at 4°C, washed with 1 x PBS, fixed with PBS-1.6% PFA, and washed with 1 x Perm/Wash Buffer (eBiosciences). After permeabilization with 1 x Perm/Wash (eBiosciences), intracellular staining was performed for 30 min at 4°C. Cells were washed, fixed in 1.6% PFA, and washed with Barcode Perm Buffer (DVS) before barcoding with a unique combination of three palladium isotopes (DVS, Fluidigm) according to the manufacturer’s recommendations. Cells were then washed with PBS and resuspended in PBS-1.6% PFA containing 0.5 μL Intercalator-Ir (DVS Sciences). Barcoded samples were pooled and stored overnight at 4°C. Before acquisition, cells were washed with milli-Q water and filtered through a cap filter with 35-μm pores (BD Biosciences). Normalization beads (Eq Beads, Fluidigm) were added to the tube and the acquisition was performed using a Helios mass cytometer (Fluidigm). Data were acquired for six consecutive days (3 animals per day).

**Data processing**
MatLab compiler software was used on FCS files to compensate for signal loss by the detector during acquisition based on the signal given by the Eq Beads. Normalized data from each acquisition were concatenated (CytoBank concatenation tool) and all conditions separated according to their barcode signal using CyTOF software (Fluidigm). In addition, as we previously describe, we used the same sample for each experiment to control the quality of each staining/acquisition and thus its reproducibility. Eq beads, dead cells, and cell doublets were excluded from the resulting FCS files, as well as nonspecifically stained CD66+CD3+ eosinophils, as previously described.

**Cell population identification**
The spanning-tree progression analyses of density-normalized events algorithm (SPADE) was used on the entire data set of macaque samples to cluster cell populations displaying similar phenotypes. The following markers were used for clustering: CD66, HLA-DR, CD3, CD64, CD8, CD123, CD11a, CD62L, CD4, FcγRI, CD86, CD172a, CD45, CD1c, CD32, CD39, CCR5, CD16, CD11c, CXCR4, CD14, CD23, CD141, CD20, CCR7, and CADM1. A random pre-downsampling of 11,478 cells (corresponding to the number of cells contained in the smallest sample) was performed on all samples to allow an equal contribution of each sample to create the tree of cell clusters. All cells from every sample were then assigned to a cluster according to their phenotype. The SPADEVizR R package was used to perform quality control on the SPADE clusters. Clusters of good quality were defined based on a narrow (IQR ≤ 2) and unimodal distribution (Hartigan’s dip test, p ≤ 0.05) for each marker. After benchmarking of SPADE parameters, the optimal SPADE used 800 clusters and a downsampling limit of 30%, resulting in 64.62% of clusters of good quality.

**Heatmap representation**
A heatmap representation of the clusters was generated using SPADEVizR according to the mean median MSI of each sample, in the same sample for each experiment to control the quality of each staining/acquisition and thus its reproducibility. Eq beads, dead cells, and cell doublets were excluded from the resulting FCS files, as well as nonspecifically stained CD66+CD3+ eosinophils, as previously described.

**Phenotypic and kinetic families**
We created phenotypic families, which grouped cell clusters that displayed similar phenotypes. This strategy avoids “over-clustering”, as clusters may account for diverse activation or maturation stages, and favors the identification of actual subpopulations by their phenotypic characteristics. The phenotypic families (PF) were grouped accordingly to their evolution at the different time points of the study. We thus grouped the PF with similar evolution trends in “kinetics families” (KF). The grouping of PF to form KF was performed using a hierarchical method based on the Pearson correlation and complete linkage.

**Negative-stain electron microscopy**
Trimer and adjuvants were co-formulated as described above (see “Adjuvants”) using the same ratios, scaled down 10-fold (i.e. total volume 0.1 mL). The formulations were incubated for 1 h at 37°C and diluted 1:10 in Tris-buffered saline before applying 3 μL onto glow-discharged carbon-coated Cu400 mesh grids (Electron Microscopy Services). The samples were blotted using filter paper and the grids were then negatively stained with 2% (w/v) uranyl formate for 60 s. Data were collected on a Tecnai Spirit transmission electron microscope, operating at 120 keV. Nominal magnification was 52,000x with a resulting pixel size of 2.05 Å at the specimen plane, and an average defocus of ~1.50 μm was used. Micrographs were recorded using a Tietz 4k x 4k TemCam-F416 CMOS camera. Data collection was performed using Leginon automated imaging interface, and data processing (particle picking, extraction and 2D classifications) was performed using the Appion data processing suite. Data processing procedures to determine amount of native-like trimers is described in detail elsewhere. Briefly, 2D class averages were visually inspected. Trimmers visually similar to
those previously described for BG505 SOSIP.664 or B41 SOSIP.664 were considered to have an overall native structure. Any particles that did not clearly show a central, triangular mass were classified as non-native.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**Statistics**

R software was employed to perform SPADE algorithm and statistical analysis related to mass cytometry was performed using SPADEVizR (available at https://github.com/tchitchek-lab/SPADEVizR) and “MASS” R package (available at https://CRAN.R-project.org/package=MASS). Comparisons of cell abundances were performed using the Mann-Whitney-Wilcoxon test, with p-values < 0.05 considered significant. No correction was applied because limited number of animals (n = 6) per groups. Because of this limitation, our intention was to use this approach to generate hypothesis rather than generalized observations. Thus, we tolerate a part of false-discovery rate in order to not exclude false negative data. Furthermore, as we performed a longitudinal follow up on the same macaque over time, comparisons are not independent to each other, so this would likely over-correct p-values.

**Linear discriminant analysis**

Linear discriminant analysis was performed using mean of non-standardized cell abundances of all individuals, to preserve the contribution of each variable to differentiate vaccine regimens for each timepoint and identify KF associated to the different vaccines. In Figure 5A, the mean KF abundances of all individual was used as entry parameters to differentiate vaccine regimens at the different timepoint. In Figure 5B, mean KF abundances for all individuals and all timepoint were employed to identify the contribution of each KF to the different vaccine regimens discrimination.

**Cytocompare**

Distributions of marker expression were compared using the CytoCompare R package to identify the contribution of each marker in the discrimination of vaccine signature. This R package use the Kolmogorov-Smirnov distance to assess the maximum distance between cumulative distribution function (CDF) of the different markers based on their median signal intensity (MSI) for dendritic cells and monocytes. Then, as we aimed to prioritize the identification of a top discriminant markers (although, all markers could be statistically discriminant), we determined the threshold of 0.5, rather than Selecting a top set of markers in each comparison with the highest KS distance as we previously reported.

**Generalized linear model**

A generalized linear model was used to assess the link between innate and adaptive responses after the two boosts. SPADEVizR R package is able to generate generalized linear models (GLM) to predict biological outcome associated to each sample based on cluster abundances. This method aims to identify a linear combination of clusters abundances that correlate with a biological outcomes from a training dataset. Based on these linear combinations, we can then predict biological outcomes for a test dataset. The abundance profiles of kinetic families for each individual 24h after the second and third injection (n = 12 for each vaccine regimen) were used as the entry parameter. The values to predict were the nAb titers, IgG binding titers and rsFcγRIIIa binding activities. Abundances 24h after the baseline were not included as no nAb were detected for this timepoint. Then, iterative linear regressions were generated until all coefficients had a p-value < 0.05. At each iteration, the coefficient having the highest p-value higher than 0.05 was removed. One value was excluded from both the IgG binding and nAb model because titers at W26 for one animal were not included in the confidence interval.